DEA Cannabis Rescheduling Hearings Face Transparency Push From Congress

Congressional pressure mounts on the Drug Enforcement Administration to provide public access to next week's cannabis rescheduling hearings, as Rep. Steve Cohen (D-TN) formally requests livestream coverage of the proceedings. The Tennessee Democrat's letter to DEA leadership underscores growing frustration with the agency's opaque handling of what represents the most consequential federal cannabis policy shift in decades.

The push for transparency comes as the DEA prepares to conduct administrative hearings on moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. This reclassification would maintain federal prohibition while enabling legitimate research and potentially opening tax advantages for state-licensed operators. The hearings represent a critical juncture in the Biden administration's cannabis policy evolution, following Health and Human Services' recommendation for rescheduling last year.

Media organizations joining the transparency campaign reflect broader industry concerns about regulatory uncertainty that continues to plague cannabis markets. Multi-state operators like Curaleaf (CURA), Green Thumb Industries (GTII), and Trulieve (TCNNF) have seen volatile trading patterns throughout the rescheduling process, with investors parsing every regulatory development for market signals. The lack of public access to these hearings compounds the information asymmetry that characterizes cannabis investing.

The DEA's resistance to livestreaming contrasts sharply with other federal agencies' embrace of public proceedings during major policy deliberations. This opacity particularly frustrates institutional investors who require clear regulatory frameworks before committing capital to cannabis assets. The rescheduling process timeline remains fluid, with implementation potentially stretching into 2025 regardless of hearing outcomes.

While rescheduling represents incremental progress rather than full legalization, the regulatory clarity it provides could unlock significant institutional investment in cannabis markets. The transparency debate surrounding these hearings illustrates the ongoing tension between federal agencies accustomed to operating behind closed doors and an industry demanding regulatory predictability to support billion-dollar valuations across public cannabis companies.